Dengue: a growing threat requiring vaccine development for disease prevention

References

• Higa Y. Dengue vectors and their spatial distribution. Trop Med Health. 2011;39:17–27.
   PubMedGoogle Scholar
• Guo C, Kim TK, Pinto AFM, et al. Global epidemiology of dengue outbreaks in 1990–2015: a systematic review and meta-analysis. Front Cell Infect Microbiol. 2017;7:317.
   PubMed Web of Science ®Google Scholar
• Brady OJ, Gething PW, Bhatt S, et al. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis. 2012;6:e1760.
   PubMed Web of Science ®Google Scholar
• Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature. 2013;496:504–507.
   PubMed Web of Science ®Google Scholar
• Vong S, Khieu V, Glass O, et al. Dengue incidence in urban and rural cambodia: results from population-based active fever surveillance, 2006–2008. PLoS Negl Trop Dis. 2010;4:e903.
   PubMed Web of Science ®Google Scholar
• Screaton G, Mongkolsapaya J, Yacoub S, et al. New insights into the immunopathology and control of dengue virus infection. Nat Rev Immunol. 2015;15:745–759.
   PubMed Web of Science ®Google Scholar
• Chapman EG, Costantino DA, Rabe JL, et al. The structural basis of pathogenic subgenomic flavivirus RNA (sfRNA) production. Science. 2014;344:307–310.
   PubMed Web of Science ®Google Scholar
• Clarke BD, Roby JA, Slonchak A, et al. Functional non-coding RNAs derived from the flavivirus 3ʹ untranslated region. Virus Res. 2015;206:53–61.
   PubMed Web of Science ®Google Scholar
• Simmons CP, Farrar JJ, Nguyen VVC, et al. Dengue. N Engl J Med. 2012;366:1423–1432.
   PubMed Web of Science ®Google Scholar
• Khetarpal N, Khanna I. Dengue fever: causes, complications, and vaccine strategies. J Immunol Res. 2016;2016:6803098.
   PubMed Web of Science ®Google Scholar
• Vannice KS, Durbin A, Hombach J, et al. Status of vaccine research and development of vaccines for dengue. Vaccine. 2016;34:2934–2938.
   PubMed Web of Science ®Google Scholar
• Salje H, Cummings DA, Rodriguez-Barraquer I, et al. Reconstruction of antibody dynamics and infection histories to evaluate dengue risk. Nature. 2018;557:719–723.
   PubMed Web of Science ®Google Scholar
• Duong V, Lambrechts L, Paul RE, et al. Asymptomatic humans transmit dengue virus to mosquitoes. Proc Natl Acad Sci U S A. 2015;112:14688–14693.
   PubMed Web of Science ®Google Scholar
• Ten Bosch QA, Fernández-Borges N, Younas N, et al. Contributions from the silent majority dominate dengue virus transmission. PLoS Pathog. 2018;14:e1006965.
   PubMed Web of Science ®Google Scholar
• Cahill ME, Conley S, DeWan AT, et al. Identification of genetic variants associated with dengue or west nile virus disease: a systematic review and meta-analysis. BMC Infect Dis. 2018;18:282.
   PubMed Web of Science ®Google Scholar
• Gupta S, Agarwal A, Kumar A, et al. Genome-wide analysis to identify HLA factors potentially associated with severe dengue. Front Immunol. 2018;9:728.
   PubMed Web of Science ®Google Scholar
• Jaenisch T, Cornick JE, Harris SR, et al. Clinical evaluation of dengue and identification of risk factors for severe disease: protocol for a multicentre study in 8 countries. BMC Infect Dis. 2016;16:120.
   PubMed Web of Science ®Google Scholar
• Whitehorn J, Smouse SL, Tau NP, et al. Genetic variants of MICB and PLCE1 and associations with the laboratory features of dengue. BMC Infect Dis. 2017;17:412.
   PubMed Web of Science ®Google Scholar
• Flores-Mendoza LK, Estrada-Jiménez T, Sedeño-Monge V, et al. IL-10 and socs3 are predictive biomarkers of dengue hemorrhagic fever. Mediators Inflamm. 2017;2017:5197592.
   PubMedGoogle Scholar
• Nhi DM, Huy NT, Ohyama K, et al. A proteomic approach identifies candidate early biomarkers to predict severe dengue in children. PLoS Negl Trop Dis. 2016;10:e0004435.
   PubMed Web of Science ®Google Scholar
• Nikolayeva I, Bost P, Casademont I, et al. A blood RNA signature detecting severe disease in young dengue patients at hospital arrival. J Infect Dis. 2018;217:1690–1698.
   PubMed Web of Science ®Google Scholar
• Vicente CR, Cornick JE, Harris SR, et al. Serotype influences on dengue severity: a cross-sectional study on 485 confirmed dengue cases in Vitória, Brazil. BMC Infect Dis. 2016;16:320.
   PubMed Web of Science ®Google Scholar
• Murphy BR, Whitehead SS. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol. 2011;29:587–619.
   PubMed Web of Science ®Google Scholar
• Wahala WMPB, Kraus AA, Haymore LB, et al. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology. 2009;392:103–113.
   PubMed Web of Science ®Google Scholar
• Wahala WMPB, De Silva AM. The human antibody response to dengue virus infection. Viruses. 2011;3:2374–2395.
   PubMed Web of Science ®Google Scholar
• Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol. 2013;158:1445–1459.
   PubMed Web of Science ®Google Scholar
• Midgley CM, Bajwa-Joseph M, Vasanawathana S, et al. An in-depth analysis of original antigenic sin in dengue virus infection. J Virol. 2011;85:410–421.
   PubMed Web of Science ®Google Scholar
• Vatti A, Monsalve DM, Pacheco Y, et al. Original antigenic sin: a comprehensive review. J Autoimmun. 2017;83:12–21.
   PubMed Web of Science ®Google Scholar
• Whitehead SS, Blaney JE, Durbin AP, et al. Prospects for a dengue virus vaccine. Nat Rev Microbiol. 2007;5:518–528.
   PubMed Web of Science ®Google Scholar
• Elong Ngono A, Chen H-W, Tang WW, et al. Protective role of cross-reactive CD8 T cells against dengue virus infection. EBioMedicine. 2016;13:284–293.
   PubMed Web of Science ®Google Scholar
• Weiskopf D, Angelo MA, Bangs DJ, et al. The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes. J Virol. 2015;89:120–128.
   PubMed Web of Science ®Google Scholar
• Chu H, George SL, Stinchcomb DT, et al. CD8+ T-cell responses in flavivirus-naive individuals following immunization with a live-attenuated tetravalent dengue vaccine candidate. J Infect Dis. 2015;212:1618–1628.
   PubMed Web of Science ®Google Scholar
• Lam JH, Reynard S, Fizet A, et al. Dengue vaccine-induced CD8+ T cell immunity confers protection in the context of enhancing, interfering maternal antibodies. JCI Insight. 2017;2(24):94500.
   Web of Science ®Google Scholar
• Vannice KS, Roehrig JT, Hombach J. Next generation dengue vaccines: a review of the preclinical development pipeline. Vaccine. 2015;33:7091–7099.
   PubMed Web of Science ®Google Scholar
• Thomas SJ, Rothman AL. Trials and tribulations on the path to developing a dengue vaccine. Vaccine. 2015;33 Suppl 4(Suppl 4):D24–D31.
   PubMedGoogle Scholar
• Barban V, Mateo M, Page A, et al. Improvement of the dengue virus (DENV) nonhuman primate model via a reverse translational approach based on dengue vaccine clinical efficacy data against DENV-2 and −4. J Virol. 2018;92(12):e00440-18.
   PubMed Web of Science ®Google Scholar
• Milligan GN, Sarathy VV, Infante E, et al. A dengue virus type 4 model of disseminated lethal infection in AG129 mice. PLoS One. 2015;10:e0125476.
   PubMed Web of Science ®Google Scholar
• Milligan GN, Sarathy VV, White MM, et al. A lethal model of disseminated dengue virus type 1 infection in AG129 mice. J Gen Virol. 2017;98:2507–2519.
   PubMed Web of Science ®Google Scholar
• Sarathy VV, White M, Li L, et al. Characterization of a murine model of non-lethal, symptomatic dengue virus infection. Sci Rep. 2018;8:4900.
   PubMed Web of Science ®Google Scholar
• Sarathy VV, Oksanen HM, Bamford JKH. Characterization of lethal dengue virus type 4 (DENV-4) TVP-376 infection in mice lacking both IFN-α/β and IFN-γ receptors (AG129) and comparison with the DENV-2 AG129 mouse model. J Gen Virol. 2015;96:3035–3048.
   PubMed Web of Science ®Google Scholar
• Flipse J, Smit JM, Simmons CP. The complexity of a dengue vaccine: a review of the human antibody response. PLoS Negl Trop Dis. 2015;9:e0003749.
   PubMed Web of Science ®Google Scholar
• Screaton G, Mongkolsapaya J. Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? the challenges of a dengue vaccine. Cold Spring Harb Perspect Biol. 2017. DOI:10.1101/cshperspect.a029520
   Web of Science ®Google Scholar
• Torresi J, Ebert G, Pellegrini M. Vaccines licensed and in clinical trials for the prevention of dengue. Hum Vaccines Immunother. 2017;13:1059–1072.
   PubMed Web of Science ®Google Scholar
• Guy B, Lang J, Saville M, et al. Vaccination against dengue: challenges and current developments. Annu Rev Med. 2016;67:387–404.
   PubMed Web of Science ®Google Scholar
• Pantoja P, Pérez-Guzmán EX, Rodríguez IV, et al. Zika virus pathogenesis in rhesus macaques is unaffected by pre-existing immunity to dengue virus. Nat Commun. 2017;8:15674.
   PubMed Web of Science ®Google Scholar
• Sariol CA, Nogueira ML, Vasilakis N. A tale of two viruses: does heterologous flavivirus immunity enhance zika disease? Trends Microbiol. 2017. DOI:10.1016/j.tim.2017.10.004
   PubMed Web of Science ®Google Scholar
• Slon Campos JL, Poggianella M, Marchese S, et al. DNA-immunisation with dengue virus E protein domains I/II, but not domain III, enhances Zika, West Nile and yellow fever virus infection. PLoS One. 2017;12:e0181734.
   PubMed Web of Science ®Google Scholar
• Rather IA, Kim TK, Pinto AFM, et al. Prevention and control strategies to counter dengue virus infection. Front Cell Infect Microbiol. 2017;7:336.
   PubMed Web of Science ®Google Scholar
• Martin J, Hermida L, Xia W-Y, et al. Dengue vaccine: an update on recombinant subunit strategies. Acta Virol. 2016;60:3–14.
   PubMed Web of Science ®Google Scholar
• Liu Y, Liu J, Cheng G, et al. Vaccines and immunization strategies for dengue prevention. Emerg Microbes Infect. 2016;5:emi201674.
   Web of Science ®Google Scholar
• Halstead SB, Russell PK, Sun G, et al. Protective and immunological behavior of chimeric yellow fever dengue vaccine. Vaccine. 2016;34:1643–1647.
   PubMed Web of Science ®Google Scholar
• Pang T, Mak TK, Gubler DJ, et al. Prevention and control of dengue-the light at the end of the tunnel. Lancet Infect Dis. 2017;17:e79–e87.
   PubMedGoogle Scholar
• Schwartz LM, Halloran ME, Durbin AP, et al. The dengue vaccine pipeline: implications for the future of dengue control. Vaccine. 2015;33:3293–3298.
   PubMed Web of Science ®Google Scholar
• Guy B, Jackson N. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nat Rev Microbiol. 2015;14(nrmicro.2015.2):45.
   PubMedGoogle Scholar
• Vannice KS, Edge C, Dunleavy U, et al. Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines. Vaccine. 2018;36:3411–3417.
   PubMed Web of Science ®Google Scholar
• Arredondo-García, J. L., Hadinegoro SR, Reynales H, et al. Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2018;24:755–763.
   PubMed Web of Science ®Google Scholar
• Sridhar S, Luedtke A, Langevin E, et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med. 2018. DOI:10.1056/NEJMoa1800820
   PubMed Web of Science ®Google Scholar
• Villar LA, Rojas DP, Besada-Lombana S, et al. Epidemiological trends of dengue disease in colombia (2000-2011): a systematic review. PLoS Negl Trop Dis. 2015;9:e0003499.
   PubMed Web of Science ®Google Scholar
• Guy B, Noriega F, Ochiai RL, et al. A recombinant live attenuated tetravalent vaccine for the prevention of dengue. Expert Rev Vaccines. 2017;16:1–13.
   PubMed Web of Science ®Google Scholar
• Capeding MR, Tran NH, Hadinegoro SRS, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet Lond Engl. 2014;384:1358–1365.
   PubMed Web of Science ®Google Scholar
• Butrapet S, Huang CY-H, Pierro DJ, et al. Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5′ noncoding region and nonstructural proteins 1 and 3. J Virol. 2000;74:3011–3019.
   PubMed Web of Science ®Google Scholar
• Huang CY-H, Butrapet S, Pierro DJ, et al. Chimeric dengue type 2 (vaccine strain pdk-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J Virol. 2000;74:3020–3028.
   PubMed Web of Science ®Google Scholar
• Kinney RM, Linder M, Wengler G, et al. Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology. 1997;230:300–308.
   PubMed Web of Science ®Google Scholar
• Huang CY-H, Butrapet S, Tsuchiya KR, et al. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J Virol. 2003;77:11436–11447.
   PubMed Web of Science ®Google Scholar
• Osorio JE, Huang CY-H, Kinney RM, et al. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine. 2011;29:7251–7260.
   PubMed Web of Science ®Google Scholar
• Rupp R, Luckasen GJ, Kristein JL, et al. Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: a phase 1b randomized study. Vaccine. 2015;33:6351–6359.
   PubMed Web of Science ®Google Scholar
• Osorio JE, Page N, Cortese MM, et al. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. Lancet Infect Dis. 2014;14:830–838.
   PubMed Web of Science ®Google Scholar
• Sirivichayakul C, Barranco-Santana EA, Esquilin-Rivera I, et al. Safety and immunogenicity of a tetravalent dengue vaccine candidate in healthy children and adults in dengue-endemic regions: a randomized, placebo-controlled phase 2 study. J Infect Dis. 2016;213:1562–1572.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Edge C, Dunleavy U, et al. A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate. Vaccine. 2018;36:3976–3983.
   PubMed Web of Science ®Google Scholar
• Swanstrom JA, Henein S, Plante JA, et al. Analyzing the human serum antibody responses to a live attenuated tetravalent dengue vaccine candidate. J Infect Dis. 2018;217:1932–1941.
   PubMed Web of Science ®Google Scholar
• Whitehead SS, Falgout B, Hanley KA, et al. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3ʹ untranslated region is highly attenuated and immunogenic in monkeys. J Virol. 2003;77:1653–1657.
   PubMed Web of Science ®Google Scholar
• Bustos-Arriaga J, Edge C, Dunleavy U, et al. Decreased accumulation of subgenomic RNA in human cells infected with vaccine candidate DEN4Δ30 increases viral susceptibility to type I interferon. Vaccine. 2018;36:3460–3467.
   PubMed Web of Science ®Google Scholar
• Durbin AP, McArthur J, Marron JA, et al. The live attenuated dengue serotype 1 vaccine rDEN1Δ30 is safe and highly immunogenic in healthy adult volunteers. Hum Vaccin. 2006;2:167–173.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick BD, Breen M, Choyke P, et al. The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model. Sci Transl Med. 2016;8:330ra36.
   PubMed Web of Science ®Google Scholar
• Danko JR, Kochel T, Simmons M, et al. Safety and immunogenicity of a tetravalent dengue DNA vaccine administered with a cationic lipid-based adjuvant in a phase 1 clinical trial. Am J Trop Med Hyg. 2018;98:849–856.
   PubMed Web of Science ®Google Scholar
• Gottschamel J, Lössl A, Ruf S, et al. Production of dengue virus envelope protein domain III-based antigens in tobacco chloroplasts using inducible and constitutive expression systems. Plant Mol Biol. 2016;91:497–512.
   PubMed Web of Science ®Google Scholar
• Coller B-AG, Clements DE, Bett AJ, et al. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine. 2011;29:7267–7275.
   PubMed Web of Science ®Google Scholar
• Diaz C, Jarman RG, Febo I, et al. Phase I randomized study of a tetravalent dengue purified inactivated vaccine in healthy adults from puerto rico. Am J Trop Med Hyg. 2018;98:1435–1443.
   PubMed Web of Science ®Google Scholar
• Lin RJ, Lee TH, Leo YS. Dengue in the elderly: a review. Expert Rev Anti Infect Ther. 2017;15:729–735.
   PubMed Web of Science ®Google Scholar
• Bravo L, Roque VG, Brett J, et al. Epidemiology of dengue disease in the philippines (2000–2011): a systematic literature review. PLoS Negl Trop Dis. 2014;8:e3027.
   PubMed Web of Science ®Google Scholar
• Dantés HG, Farfán-Ale JA, Sarti E, et al. Epidemiological trends of dengue disease in mexico (2000–2011): a systematic literature search and analysis. PLoS Negl Trop Dis. 2014;8:e3158.
   PubMed Web of Science ®Google Scholar
• L’Azou M, Taurel A-F, Flamand C, et al. Recent epidemiological trends of dengue in the french territories of the Americas (2000–2012): a systematic literature review. PLoS Negl Trop Dis. 2014;8:e3235.
   PubMed Web of Science ®Google Scholar
• Teixeira MG, Siqueira JB Jr, Ferreira GLC, et al. Epidemiological trends of dengue disease in brazil (2000–2010): a systematic literature search and analysis. PLoS Negl Trop Dis. 2013;7:e2520.
   PubMed Web of Science ®Google Scholar
• Limkittikul K, Brett J, L’Azou M, et al. Epidemiological trends of dengue disease in thailand (2000–2011): a systematic literature review. PLoS Negl Trop Dis. 2014;8:e3241.
   PubMed Web of Science ®Google Scholar
• Mohd-Zaki AH, Brett J, Ismail E, et al. Epidemiology of dengue disease in malaysia (2000–2012): a systematic literature review. PLoS Negl Trop Dis. 2014;8:e3159.
   PubMed Web of Science ®Google Scholar
• Rigau-Pérez JG, Vorndam AV, Clark GG, et al. The dengue and dengue hemorrhagic fever epidemic in Puerto Rico, 1994-1995. Am J Trop Med Hyg. 2001;64:67–74.
   PubMedGoogle Scholar
• Rahman M, Rahman K, Siddque AK, et al. First outbreak of dengue hemorrhagic fever, Bangladesh. Emerg Infect Dis. 2002;8:738–740.
   PubMed Web of Science ®Google Scholar
• Lee VJ, Lye DCB, Sun Y, et al. Predictive value of simple clinical and laboratory variables for dengue hemorrhagic fever in adults. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2008;42:34–39.
   Web of Science ®Google Scholar
• Surveillance de la dengue à la Réunion. Point épidémiologique au 23 avril 2018./2018/Océan Indien/Tous les numéros/Points épidémiologiques/Publications et outils/Accueil. [ cited 2018 Jul 26]. Available from: http://invs.santepubliquefrance.fr/Publications-et-outils/Points-epidemiologiques/Tous-les-numeros/Ocean-Indien/2018/Surveillance-de-la-dengue-a-la-Reunion.-Point-epidemiologique-au-23-avril-2018
   Google Scholar
• Lee -C-C, Hsu H-C, Chang C-M, et al. Atypical presentations of dengue disease in the elderly visiting the ED. Am J Emerg Med. 2013;31:783–787.
   PubMed Web of Science ®Google Scholar
• Rowe EK, Leo Y-S, Wong JGX, et al. Challenges in dengue fever in the elderly: atypical presentation and risk of severe dengue and hospita-acquired infection. PLoS Negl Trop Dis. 2014;8:e2777.
   PubMed Web of Science ®Google Scholar
• García-Rivera EJ, Rigau-Pérez JG. Dengue severity in the elderly in Puerto Rico. Rev Panam Salud Publica Pan Am J Public Health. 2003;13:362–368.
   PubMedGoogle Scholar